Current Liabilities
Other Commercial Liabilities
Vertex Pharmaceuticals Other Commercial Liabilities increased by 0.4% to $2.98B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.1%, from $2.95B to $2.98B. Over 5 years (FY 2020 to FY 2025), Other Commercial Liabilities shows an upward trend with a 16.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
Metric ID:
commercial_liabilities_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.48B | $1.58B | $1.68B | $1.72B | $2.12B | $2.26B | $2.13B | $2.33B | $2.60B | $2.91B | $2.66B | $2.80B | $2.94B | $3.22B | $2.79B | $2.95B | $3.27B | $3.61B | $2.97B | $2.98B |
| QoQ Change | — | +6.9% | +5.9% | +2.5% | +23.2% | +6.8% | -6.1% | +9.4% | +11.7% | +11.9% | -8.7% | +5.3% | +5.2% | +9.5% | -13.4% | +5.9% | +10.8% | +10.5% | -17.8% | +0.4% |
| YoY Change | — | — | — | — | +43.0% | +42.9% | +26.7% | +35.2% | +22.6% | +28.4% | +24.9% | +20.2% | +13.2% | +10.7% | +5.0% | +5.6% | +11.2% | +12.2% | +6.5% | +1.1% |
Range$1.48B – $3.61B
CAGR+15.9%
Avg YoY Growth+19.3%
Median YoY Growth+16.7%
Other Commercial Liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's other commercial liabilities?
- Vertex Pharmaceuticals (VRTX) reported other commercial liabilities of $2.98B in Q1 2026.
- How has Vertex Pharmaceuticals's other commercial liabilities changed year-over-year?
- Vertex Pharmaceuticals's other commercial liabilities increased by 1.1% year-over-year, from $2.95B to $2.98B.
- What is the long-term trend for Vertex Pharmaceuticals's other commercial liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's other commercial liabilities has grown at a 16.2% compound annual growth rate (CAGR), from $1.41B to $2.97B.